Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma

Translational Research

Volumn 165, Issue 6, 2015, Pages 641-650

  Borsi, Enrica ^a   Terragna, Carolina ^a   Brioli, Annamaria ^a   Tacchetti, Paola ^a   Martello, Marina ^a   Cavo, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BORTEZOMIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; INITIATION FACTOR 4E; INTERLEUKIN 6; INTERLEUKIN 8; LENALIDOMIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; SMALL INTERFERING RNA; SOMATOMEDIN C; STAT3 PROTEIN; SURVIVIN; VASCULOTROPIN; VASCULOTROPIN A; VON HIPPEL LINDAU PROTEIN; ANTINEOPLASTIC AGENT; HIF1A PROTEIN, HUMAN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; DRUG TARGETING; HUMAN; HYPOXIA; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; CELL HYPOXIA; DRUG EFFECTS; METABOLISM;

ANTINEOPLASTIC AGENTS; CELL HYPOXIA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MULTIPLE MYELOMA;

EID: 84929274522     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2014.12.001     Document Type: Review

References (62)

1. M. Cavo, P. Tacchetti, and F. Patriarca Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study Lancet 376 2010 2075 2085
2. M. Cavo, and M. Baccarani The changing landscape of myeloma therapy N Engl J Med 354 2006 1076 1078
3. M. Cavo, S.V. Rajkumar, and A. Palumbo International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation Blood 117 2011 6063 6073
4. M. Cavo, F. Di Raimondo, and E. Zamagni Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma J Clin Oncol 27 2009 5001 5007
5. A. Palumbo, S.V. Rajkumar, and J.F. San Miguel International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation J Clin Oncol 32 2014 587 600
6. M. Dimopoulos, A. Spencer, and M. Attal Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma N Engl J Med 357 2007 2123 2132
7. S.K. Martin, P. Diamond, and S. Gronthos The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma Leukemia 25 2011 1533 1542
8. K. Asosingh, H. De Raeve, and M. de Ridder Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression Haematologica 90 2005 810 817
9. S. Colla, S. Tagliaferri, and F. Morandi The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis Blood 110 2007 4464 4475
10. S. Colla, P. Storti, and G. Donofrio Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells Leukemia 24 2010 1967 1970
11. P. Storti, M. Bolzoni, and G. Donofrio Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction Leukemia 27 2013 1697 1706
12. E. Borsi, G. Perrone, and C. Terragna Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma Oncotarget 5 2014 1761 1769
13. E. Borsi, G. Perrone, and C. Terragna HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment Exp Cell Res 328 2014 444 455
14. G.L. Semenza, and G.L. Wang A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation Mol Cell Biol 12 1992 5447 5454
15. G.H. Danet, Y. Pan, and J.L. Luongo Expansion of human SCID-repopulating cells under hypoxic conditions J Clin Invest 112 2003 126 135
16. B. Keith, R.S. Johnson, and M.C. Simon HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression Nat Rev Cancer 12 2012 9 22
17. R.H. Wenger, and M. Gassmann Oxygen(es) and the hypoxia-inducible factor-1 Biol Chem 378 1997 609 616
18. G.L. Wang, and G.L. Semenza Purification and characterization of hypoxia-inducible factor 1 J Biol Chem 270 1995 1230 1237
19. G.L. Wang, B.H. Jiang, and E.A. Rue Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension Proc Natl Acad Sci U S A 92 1995 5510 5514
20. B.H. Jiang, G.L. Semenza, and C. Bauer Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension Am J Phys 271 1996 80
21. R.K. Bruick, and S.L. McKnight A conserved family of prolyl-4-hydroxylases that modify HIF Science 294 2001 1337 1340
22. M. Ivan, K. Kondo, and H. Yang HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing Science 292 2001 464 468
23. P. Jaakkola, D.R. Mole, and Y.M. Tian Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation Science 292 2001 468 472
24. P.C. Mahon, K. Hirota, and G.L. Semenza FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity Genes Dev 15 2001 2675 2686
25. D. Lando, D.J. Peet, and J.J. Gorman FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor Genes Dev 16 2002 1466 1471
26. D. Lando, D.J. Peet, and D.A. Whelan Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch Science 295 2002 858 861
27. N.S. Chandel, and M.C. Simon Hypoxia-inducible factor: roles in development, physiology, and disease Cell Death Differ 15 2008 619 620
28. T.G. Smith, P.A. Robbins, and P.J. Ratcliffe The human side of hypoxia-inducible factor Br J Haematol 141 2008 325 334
29. G.L. Semenza Targeting HIF-1 for cancer therapy Nat Rev Cancer 3 2003 721 732
30. F. Agani, and B.-H.H. Jiang Oxygen-independent regulation of HIF-1: novel involvement of PI3K/AKT/mTOR pathway in cancer Curr Cancer Drug Targets 13 2013 245 251
31. G.L. Semenza Oxygen homeostasis Wiley Interdiscip Rev Syst Biol Med 2 2010 336 361
32. G.L. Semenza Hypoxia-inducible factors in physiology and medicine Cell 148 2012 399 408
33. S. Wellmann, M. Guschmann, and W. Griethe Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF Leukemia 18 2004 926 933
34. Y. Jiang, Z.H.H. Xue, and W.Z.Z. Shen Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1 alpha that augments transcriptional activity of CCAAT/enhancer-binding protein-alpha Leukemia 19 2005 1239 1247
35. R. Ravi, B. Mookerjee, and Z.M. Bhujwalla Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha Genes Dev 14 2000 34 44
36. O. Stoeltzing, M.F. McCarty, and J.S. Wey Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation J Natl Cancer Inst 96 2004 946 956
37. L. Li, X. Lin, and M. Staver Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo Cancer Res 65 2005 7249 7258
38. T. Hiraga, S. Kizaka-Kondoh, and K. Hirota Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer Cancer Res 67 2007 4157 4163
39. D. Liao, C. Corle, and T.N. Seagroves Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression Cancer Res 67 2007 563 572
40. W. Zundel, C. Schindler, and D. Haas-Kogan Loss of PTEN facilitates HIF-1-mediated gene expression Genes Dev 14 2000 391 396
41. G.L. Semenza Evaluation of HIF-1 inhibitors as anticancer agents Drug Discov Today 12 2007 853 859
42. E.B. Rankin, and A.J. Giaccia The role of hypoxia-inducible factors in tumorigenesis Cell Death Differ 15 2008 678 685
43. D.J. Ceradini, A.R. Kulkarni, and M.J. Callaghan Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1 Nat Med 10 2004 858 864
44. X.H. Peng, P. Karna, and Z. Cao Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression J Biol Chem 281 2006 25903 25914
45. G.L. Semenza Hypoxia-inducible factor 1: regulator of mitochondrial metabolism and mediator of ischemic preconditioning Biochim Biophys Acta 1813 2010 1263 1268
46. J.E. Jung, H.G. Lee, and I.H. Cho STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells FASEB J 19 2005 1296 1298
47. Q. Xu, J. Briggs, and S. Park Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways Oncogene 24 2005 5552 5560
48. R.S. Belaiba, S. Bonello, and C. Zähringer Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells Mol Biol Cell 18 2007 4691 4697
49. J. Rius, M. Guma, and C. Schachtrup NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha Nature 453 2008 807 811
50. P. van Uden, N.S. Kenneth, and S. Rocha Regulation of hypoxia-inducible factor-1alpha by NF-kappaB Biochem J 412 2008 477 484
51. B.M. Emerling, F. Weinberg, and J.-L.L. Liu PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a) Proc Natl Acad Sci U S A 105 2008 2622 2627
52. D.H. Shin, Y.-S.S. Chun, and D.S. Lee Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1 Blood 111 2008 3131 3136
53. C.S. Mitsiades, N.S. Mitsiades, and C.J. McMullan Antimyeloma activity of heat shock protein-90 inhibition Blood 107 2005 1092 1100
54. J. Zhang, M. Sattler, and G. Tonon Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma Cancer Res 69 2009 5082 5090
55. F. Takahashi, S. Akutagawa, and H. Fukumoto Osteopontin induces angiogenesis of murine neuroblastoma cells in mice Int J Cancer 98 2002 707 712
56. Y. Hu, K. Kirito, and K. Yoshida Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan Mol Cancer Ther 8 2009 2329 2338
57. J. Hu, D.R. Handisides, and E. Van Valckenborgh Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug Blood 116 2010 1524 1527
58. H. Zhong, A.M. De Marzo, and E. Laughner Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases Cancer Res 59 1999 5830 5835
59. L. Lu, F. Payvandi, and L. Wu The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions Microvasc Res 77 2009 78 86
60. R. Ria, I. Catacchio, and S. Berardi HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target Clin Cancer Res 20 2014 847 858
61. L.M. Greenberger, I.D. Horak, and D. Filpula A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth Mol Cancer Ther 7 2008 3598 3608
62. B. Vester, and J. Wengel LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA Biochemistry 43 2004 13233 13241